Argenica awarded $1.2m grant for traumatic brain injury project
WA-based biotechnology company Argenica Therapeutics has attracted a $1.2 million grant for work on a potential therapeutic drug for mild and moderate...
Continue reading
This website may not work correctly in Internet Explorer. We recommend switching to a more secure modern web browser such as Microsoft Edge which is already installed on your computer.
Our TBI Neurotrauma Research Group is led by Professor Melinda (Lindy) Fitzgerald whose previous contributions include identifying the cells that are particularly vulnerable to oxidative damage that occurs as degeneration spreads following injury to the central nervous system.
The group hope to understand whether oxidative damage to the DNA of oligodendrocytes (the cells that make insulating myelin in the brain) is a feature that unifies neurotrauma, neurodegenerative and demyelinating disease. The research may identify a potential target for early preventative treatment in all three conditions.
In addition, the team are engaging in clinical initiatives to fill gaps in knowledge surrounding TBI of all severities. Our group will design a way to confidentially gather data on treatment and outcomes of TBI in all states and territories in Australia, including those in rural, remote and Aboriginal communities. This information will help to personalise care for individuals who experience TBI and determine which treatments work best for specific symptoms and individuals, to improve the lives of Australians with TBI.
Keep informed with our latest updates.
Stay up to date with our latest news and announcements.